Titan: FDA Clearance of IND Application for Nalmefene Implant

 Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder ("OUD").

https://www.biospace.com/article/releases/titan-pharmaceuticals-announces-fda-clearance-of-ind-application-for-nalmefene-implant/